Alzheimer’s is a chronic disease which starts slowly but turns swear gradually. Usually, it

is common in the patients with Dementia. Dementia is a broad category of brain disease

cause decrease in ability to think, while Huntington’s disease is inherited a progressive

form of dementia.


Usually, 60% to 70% of Dementia cases face Alzheimer’s. The most common early

symptom is short term memory loss i.e. facing difficulty in remembering recent events

others are forgetting names of friends or family and confusion in situations. With the

passage of time symptoms varies which includes disorientation, problems with language,

loss of motivation, mood swings, not managing self­care and behavioral issues. Persons

facing this disease often withdraw from family as well as society. Eventually, bodily

functions are lost, ultimately results in the death of the patient. It is a very severe problem

of many countries.


LMTX is TauRx’s second generation TAI (tau aggregation inhibitor). LMTX has a

chemical structure similar to a dye called methylene blue used as stain and medication.

Being similar to stain LMTX colors Patient’s urine bluish green. LMTX is used as medicine

for Alzheimer patients.


The researchers recruited 850+ patients from almost 16 countries. These patients were

split into three groups .The first group received a lower dose, the second group received a

higher dose and the third group was given LMTX in a very small amount so that color of

their urine couldn’t change and they wouldn’t suspect that they were part of the research.

Unfortunately, the drug failed. Almost 85% of patients who took LMTX showed no

improvement in symptoms. But according to TauRx rest of the 15% patients who took this

drug showed no decrease in cognitive skills. This means for these patients Alzheimer

stopped progressing during the trial period.


Claude Wischik, a founder and the chief executive of TauRx, spoke from Toronto at the

Alzheimer’s Association International Conference that, there were highly significant

effects in patients taking the drug alone, and no effect in patients taking it as an add­on.

Although this drug only slows down the Alzheimer symptoms but its results are

unprecedented compared as compared with anyone else said by CEO.


Many biochemical tests have been developed to diagnose condition before

symptoms begin. These tests prove beneficial in preventing this disease. Moreover,

intellectual activities such as playing chess can reduce the risk of AD although no casual

or practical relationship can be found. Although LMTX fails to cure this disease but still it

can stop the symptoms of Alzheimer by 80 per cent. Whether LMTX works or not, It is

clear that pharmaceutical companies and scientists will keep trying. TauRx has completed

2 Phase 3 clinical trials of LMTX in Alzheimer’s. An abstract from the 1st of its two phase

3 trials was presented at Alzheimer’s Association International Conference (AAIC) in

Toronto, on 27th July 2016.Results are predictable to be available in August.

By recent survey, it is revealed that Alzheimer is affecting US economy by $200 billion

annually. An effective treatment can save many lives and money